PROM1 and brain neoplasm: A study on the immunogenicity of CD133 + brain tumor stem cells (BTSCs) has shown a downregulation in MHC class-I (MHC I) expression or NK cell activating ligands on the majority of CD133 + cells, which may make these cells resistant to the adaptive and innate immune surveillance [79].